Analyst Upgrades: JCPenney, First Solar, and ACADIA

Analysts upwardly revised their ratings on J C Penney Company Inc (JCP), First Solar, Inc. (FSLR), and ACADIA Pharmaceuticals Inc. (ACAD)

Feb 24, 2015 at 9:20 AM
facebook twitter linkedin


Analysts are weighing in today on department store chain J C Penney Company Inc (NYSE:JCP), alternative energy issue First Solar, Inc. (NASDAQ:FSLR), and drugmaker ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD). Here's a quick roundup of today's bullish brokerage notes on JCP, FSLR, and ACAD.

  • JCP is pointed 1.5% higher ahead of the open, after Piper Jaffray underscored the stock's status as a "Top Pick for 2015," along with an "overweight" rating and $12 price target. The bullish note comes as little surprise, considering J C Penney Company Inc has advanced 30.7% year-to-date to trade at $8.47. Options traders are in the bulls' corner, as well. The stock's 10-day International Securities Exchange (ISE), Chicago Board Options Exchange (CBOE), and NASDAQ OMX PHLX (PHLX) call/put volume ratio of 4.65 ranks just 4 percentage points from a 12-month high. Looking ahead, JCP will report fourth-quarter earnings Thursday evening, and the Street is looking for a per-share profit of 11 cents.

  • FSLR, which will step into the confessional tonight, is up 15% ahead of the bell. Powering the move higher is news of a potential joint venture with sector peer SunPower Corporation (NASDAQ:SPWR), as well as a subsequent upgrade to "buy" from "hold" at Deutsche Bank -- which also raised its price target to $68 from $60. On the charts, First Solar, Inc. has had a solid start to 2015, tacking on more than 11% to trade at $49.64. Option bulls have responded, too, as the equity's 10-day ISE/CBOE/PHLX call/put volume ratio of 3.31 sits in the 81st percentile of its annual range.

  • Finally, ACAD has surged 18.5% year-to-date to perch at $37.62, and is pointed 1.7% higher -- and headed for record-high territory -- in pre-market trading, after H.C. Wainwright initiated coverage with a "buy" rating and $50 price target. This bullish brokerage attention is just more of the same for ACADIA Pharmaceuticals Inc., which has received seven "strong buy" recommendations, compared to one "hold" and not a single "sell." Meanwhile, the company will divulge fourth-quarter numbers after the close this Thursday, with at least one group of option players gambling on post-event upside.
 

 

 

These investors are using the market's volatility to their advantage and scoring triple-digit gains on many of their trades.

Even in today's sideways bear market, this trading strategy has continued to provide consistency and profitability to a small group of investors. By using this approach, these traders are removing directional risk and still hitting triple-digit returns. If you want access to this strategy, and lower risk with higher returns sounds good to you, then don't wait another minute.

Join us now to receive our next trades the moment they come out!

 

Common mistakes options traders make
 


 


 
Special Offers from Schaeffer's Trading Partners